OriGene Technologies Acquires Beijing Zhongshan Golden Bridge Biotechnology

OriGene Technologies, Inc. announced today the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio).

Founded in the year 1993, ZsBio provides testing products (pathology) within their domestic Chinese market, such as oncology diagnostics.

OriGene had the following to say regarding today’s acquisition, “With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene,” said Wei-Wu He, CEO of OriGene.  “ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative highly specific monoclonal antibodies and assays to complement and strengthen ZsBio’s portfolio of products.”

In a market that has experienced double-digit market growth annually, OriGene hopes the acquisition of ZsBio bolsters their bottom-line.

OriGene Technologies, Inc., is a biosciences company dedicated to develop gene centric innovative products and services to improve the quality of healthcare diagnostics and treatments while ZsBio has more than 25 years of pathology diagnostics experience in China.



Latest News

Twilio Inc  General Counsel Sells $3,074,866.60 in Stock
Twilio Inc General Counsel Sells $3,074,866.60 in Stock
Lam Research  Updates Q4 2019 Earnings Guidance
Lam Research Updates Q4 2019 Earnings Guidance
Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc  to Announce -$0.97 Earnings Per Share
Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc to Announce -$0.97 Earnings Per Share
NPER  Market Capitalization Achieves $222,981.00
NPER Market Capitalization Achieves $222,981.00
Centurylink  Hits New 12-Month Low at $11.51
Centurylink Hits New 12-Month Low at $11.51
Core Laboratories  Updates Q2 2019 Earnings Guidance
Core Laboratories Updates Q2 2019 Earnings Guidance


© 2006-2019 Ticker Report